British Columbia BCBid #PHSA 19229

Direct Award of Darbepoetin alfa (Aranesp) to Amgen Canada Inc. for ESA Supply

This opportunity involves a direct contract award for a critical pharmaceutical product in the Canadian healthcare market. - Government Buyer: - Provincial Health Services Authority (PHSA) of British Columbia - OEMs and Vendors: - Amgen Canada Inc. (OEM and supplier of Darbepoetin alfa/Aranesp) - Janssen Inc. (previous supplier of Eprex/epoetin alfa, now discontinued) - Products/Services Requested: - Darbepoetin alfa (Aranesp), an Erythropoietin Stimulating Agent (ESA) - No specific part numbers or quantities provided - Unique or Notable Requirements: - Direct award justified due to Aranesp becoming the only ESA available in Canada - Janssen's Eprex is being discontinued, leaving no alternative ESA products - No biosimilar alternatives are currently approved in Canada - The contract is valued at approximately $83.6 million over five years - Written objections from vendors are permitted

Description

The Provincial Health Services Authority (PHSA) intends to directly award a contract to Amgen Canada Inc. for the supply of Erythropoietin Stimulating Agents - Darbepoetin alfa (Aranesp) for a term of five years. This direct award is due to the absence of competition for technical reasons, as Aranesp will become the sole ESA product available in the Canadian market following the discontinuation of a competing product. The estimated contract value is $83.6 million. Vendors may submit objections by July 27, 2026, for consideration.

View original listing